Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Total Debt (2016 - 2017)

Corcept Therapeutics' Total Debt history spans 2 years, with the latest figure at $4.6 million for Q2 2017.

  • For Q2 2017, Total Debt fell 79.49% year-over-year to $4.6 million; the TTM value through Jun 2017 reached $4.6 million, down 79.49%, while the annual FY2016 figure was $14.7 million, N/A changed from the prior year.
  • Total Debt for Q2 2017 was $4.6 million at Corcept Therapeutics, down from $10.1 million in the prior quarter.
  • Across five years, Total Debt topped out at $25.0 million in Q1 2016 and bottomed at $4.6 million in Q2 2017.